Shares of Singapore-listed Singapore eDevelopment (“SeD”) surged as much as 79% to 10 cents in post-lunch trading after it announced in-vitro success of its biotechnologies against Covid-19 in independent laboratory testing.
Impact Biomedical and and its strategic partner, US-based Global Research and Discovery Group Sciences (“GRDG”), contracted an independent university laboratory to challenge the compounds against the SARS-CoV-2 virus in their advanced Biosafety Level 3 containment facilities. Equivir is successful as a treatment as well as a prophylactic to protect cells against infection of the virus, said Impact Biomedical. Currently no known COVID-19 prophylactics have been developed. |
||||||||||||||||
| GRDG is in active engagement with large global corporations to position the technologies for rapid integration into multiple distribution routes to deploy these life-saving solutions worldwide. "Our intention in relation to the Covid-19 situation is to establish strong novel research data which will then be further developed and licensed to a major pharmaceutical company for integration and eventual deployment as treatments for diseases." |
What's the relation between Impact Biomedical and GRDG?
"SeD, through its subsidiary, is responsible for all of GRDG’s costs including staff salaries, office rentals and all related expenses. In addition, SeD will support all scientific efforts and laboratory works by GRDG. In return, SeD will co-own the patents." (See SeD's announcement)
 "I am happy to see that the 3F and Equivir biological counter measures are performing as expected in independent efficacy testing. These positive results against the SARS-COV-2 virus now allow us to expeditiously move Equivir to clinical trials which we expect to be completed within the year. The 3F technology is ready for deployment in consumer products now.”-- Daryl Thompson, Director of Scientific Initiatives and founder of GRDG |
3F Biofragrance is successful as a surface disinfectant by killing the virus in concentrations as low as 1/5000 after 15 seconds, said Impact Biomedical.
"These in vitro results confirm the predictions of advanced computational molecular docking which showed that Equivir and Linebacker had binding with high affinity to the COVID-19 helicase and protease."
Equivir and Linebacker also cause transformational changes to the ACE-2 receptor which interfere with the ability of the virus to interact with the receptor and infect the host cell, said Impact Biomedical.
Binding affinity for components of 3F Biofragrance was also observed in molecular docking.
Impact Biomedical said Equivir:
| » is patented and designed as a prophylactic to be deployed in a manner similar to a vitamin. » works by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells. » treats and protects against diseases caused also by other dangerous pathogens. » has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19. |
As for Linebacker, it was created to shadow the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs.
Linebacker is under continuing research against COVID-19 as it showed efficacy against SARS and MERS in previous laboratory testing.
Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson’s, many types of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and Ebola.
3F Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect large numbers of people where they gather such as containment areas, ports of entry, train stations, airports, convention centers, offices, schools, and hospitals.
3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET, said Impact Biomedical.
3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19, said Impact Biomedical.
3F Biofragrance was developed in collaboration with Chemia Corporation (“Chemia”), world-renowned for the development of fragrances and flavors for personal, household, and industrial applications.
The combination of GRDG’s advanced scientific research and Chemia’s expert formulation and global scale production infrastructure makes this patent pending technology powerful and effective at protecting people from deadly pathogens and insects, said Impact Biomedical.
| • GRDG’s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. Dr. Moore said, “GRDG’s novel strategy of attacking diseases in multiple different ways is the future of effective pandemic response.” • GRDG’s Chief Strategy Advisor is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer. He also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). He said, “The validation of these solutions demonstrates GRDG’s skill in providing comprehensive solutions to global health threats.” • Mr. Chan Heng Fai, CEO of SeD, said: “I am greatly encouraged with the results and the team’s contribution to this cause. We hope this will eventually prove to be beneficial to everyone and we look forward to more exciting discoveries.” |
The SeD press release is here.
